BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its collaboration with VELL Health, a technology leader in wellness and holistic health, to introduce a groundbreaking holistic health and wellness application for people with Type 2 Diabetes in Guyana. This innovative initiative is part of Guyana’s nationwide pilot program for diabetes clinics which aims to improve healthcare by leveraging mobile technology, data sciences, and holistic health approaches.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that it has signed a collaborative agreement with Grupo Terralpe, Inc., a renowned private investment group based in Mexico City and Boston, Mass. Together, the companies will commercialize the pstateDx™ test, BPGbio’s prostate cancer diagnostic test, in Mexico.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that it will continue clinical validation of a novel breast cancer diagnostic panel that was developed under a previous agreement with the Department of Defense’s Clinical Breast Care Project (CBCP), including the DoD’s Uniformed Services University of the Health Sciences (USU), The Windber Research Institute, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). The new panel, developed with AI, is designed to identify women who are diagnosed with ER+ breast cancer but do not respond to hormone therapy, so that more effective options could be offered to improve treatment response.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that novel data insights from its oncology therapeutics and diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023.